2,500,000+ women treated
When you discuss the NovaSure procedure with your patients, you can recommend it with confidence. In multiple clinical studies over 10 years, the NovaSure procedure has demonstrated high amenorrhea rates when compared to other global endometrial ablation devices. And to date, more than 2.5 million procedures have been performed1.
Proven to reduce debilitating symptoms
Published 10 year data review
A data review is available in the Ten-year Review of Global Endometrial Ablation with the NovaSure Device. This article examines the peer-reviewed literature describing prospective studies that report amenorrhea rates, patient satisfaction and surgical reintervention rates following the NovaSure endometrial ablation procedure.
Methodology: Ten prospective studies, six single-arm NovaSure trials and four randomized controlled trials were reviewed for amenorrhea rate, success rate, reintervention rate and patient satisfaction. The follow-up period for these measures was 6-60 months.
Long-standing, extensive prospective clinical data clearly demonstrate that the NovaSure endometrial ablation system is a global leader, delivering outstanding results2:
Results demonstrated at 5 year follow-up
A study by Gallinat A. et al. was conducted to assess the safety, efficacy and data durability of the NovaSure endometrial ablation system five years after the procedure was conducted in women with severe menorrhagia secondary to dysfunctional uterine bleeding (DUB). Long-term clinical results indicate that the NovaSure system is a safe and effective method for treatment of women with menorrhagia secondary to DUB, yielding high amenorrhea and success rates and low surgical reintervention rates five years after treatment.
Proven success rates
Exceptional amenorrhea rates
Lowest re-intervention rates
*At 5 years, follow-up data available for 103/107 patients
1. Hologic data on file 2. Gimpelson R, Ten-year literature review of global endometrial ablation with the NovaSure device, Int J of Women’s Health, 2014.